Pharmaceuticals: A lot to say about BMS Q4 results for European companies

News published on January Friday 25, 2013
Share on

Yesterday BMS released its fourth quarter numbers with an interesting read-across to several European companies in terms of product performance. Plavix and Avapro of course are interesting to observe although less than before; Sprycel (for Novartis’s CML franchise), the Onglyza family (for AstraZeneca as a partner and Novartis as a competitor), Erbitux (for Merck KGaA) and Yervoy (for Roche’s Zelboraf) also give food for thought. It is too early to drive any conclusion about Eliquis. 

Full report available to subscribers
Please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities